|
|
|
Galectin Therapeutic 
|
2.24 -0.05 (-0.02%) |
02-26 16:00 |
Open: |
2.27 |
Pre close: |
2.29 |
Target:
|
2.74
|
High: |
2.29 |
Low: |
2.1501 |
Resistance:
|
2.35
2.67 
|
Volume: |
229,225 |
Market Cap: |
128M |
Support:
|
1.82
1.51
|
|
|
|
Technical Analysis |
Moving Averages |
MA(5):
|
2.28
 |
MACD |
MACD(12,26):
|
0.01  |
MA(20): |
2.31  |
Signal(12,26,9): |
0.02  |
MA(100): |
2.48  |
Stochastic Oscillator |
%K(14,3):
|
28.73  |
MA(250): |
2.53  |
%D(3): |
35.52  |
Average Volume(K) |
3-Month: |
32731
|
52-Week |
High:
|
3.85 |
10-Days: |
27981 |
Low: |
1.50 |
RSI |
RSI(14):
|
45.07  |
Change(%): |
1.8 |
Financials, Statistics and Valuation |
EPS |
-0.391 |
Return on Equity (ttm) |
-51.2 |
Shares Out. (M) |
57.08 |
EPS Est. Current Year |
-0.530 |
Return on Assets (ttm) |
-30.7 |
Shares Float (M) |
41.20 |
EPS Est. Next Year |
-0.520 |
PEG Ratio |
0.00 |
% Held by Insiders |
29.00 |
EPS Est. Next Quarter |
-0.130 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
17.34 |
Forward EPS |
-0.380 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
4530 |
Book Value (p.s.) |
0.510 |
EBITDA (p.s.) |
0.000 |
P/E |
-5.73 |
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
4.39 |
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-18.95 |
P/S |
0.00 |
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-11.30 |
P/CF |
-6.75 |
|
|
|
|
|